If there's anxiety lingering after the FDA's summer ruling about potential cancer toxicity with peroxisome proliferator-activated receptors (PPARs), you wouldn't know it from Wyeth - which entered a potential $372 million deal with Plexxikon Inc. to develop treatments for diabetes and metabolic disorders. (BioWorld Today)